Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Regenecare® in the Treatment of Skin Rash Associated With Cetuximab (Erbitux®) or Other EGFR Treated Cancer Patients

NCT00498992 is registered in ClinicalTrials.gov with Ingalls Memorial Hospital as lead sponsor.

NCT NCT00498992
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00498992 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Regenecare® in the Treatment of Skin Rash Associated With Cetuximab (Erbitux®) or Other EGFR Treated Cancer Patients
Lead sponsor
Ingalls Memorial Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
July 31, 2006
Completion date
Not reported
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dermatologic complications, unspecified adult solid tumor, protocol specific